



# Corrigendum: Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes

Babak Arjmand<sup>1\*</sup>, Shayesteh Kokabi Hamidpour<sup>1</sup>, Sepideh Alavi-Moghadam<sup>1</sup>, Hanieh Yavari<sup>1</sup>, Ainaz Shahbazbadr<sup>1</sup>, Mostafa Rezaei-Tavirani<sup>2</sup>, Kambiz Gilany<sup>3,4</sup> and Bagher Larjani<sup>5\*</sup>

<sup>1</sup>Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, <sup>2</sup>Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, <sup>3</sup>Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran, <sup>4</sup>Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran, <sup>5</sup>Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

**Keywords:** cancer, cancer stem cells, drug designing, metabolic processes, molecular docking

## OPEN ACCESS

### Edited and reviewed by:

Linsheng Liu,  
The First Affiliated Hospital of  
Soochow University, China

### \*Correspondence:

Babak Arjmand  
barjmand@sina.tums.ac.ir  
Bagher Larjani  
emrc@tums.ac.ir

### Specialty section:

This article was submitted to  
Translational Pharmacology,  
a section of the journal  
Frontiers in Pharmacology

**Received:** 09 March 2022

**Accepted:** 06 April 2022

**Published:** 02 May 2022

### Citation:

Arjmand B, Kokabi Hamidpour S,  
Alavi-Moghadam S, Yavari H,  
Shahbazbadr A, Rezaei-Tavirani M,  
Gilany K and Larjani B (2022)  
Corrigendum: Molecular Docking as a  
Therapeutic Approach for Targeting  
Cancer Stem Cell  
Metabolic Processes.  
Front. Pharmacol. 13:892656.  
doi: 10.3389/fphar.2022.892656

## A Corrigendum on

### Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes

by Arjmand, B., Hamidpour, S. K., Alavi-Moghadam, S., Yavari, H., Shahbazbadr, A., Tavirani, M. R., and Larjani, B. (2022). *Front. Pharmacol.* 13:768556. doi: 10.3389/fphar.2022.768556

In the published article, there was an error in affiliation 3, 4, 5. Instead of “3 Reproductive Immunology Research Center, Avicenna Research Institute (ARI), Tehran, Iran, 4 Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium, 5 Breast Cancer Research Center, Motamed Cancer Institute, Tehran, Iran”, it should be “3 Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran, 4 Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran, 5 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Arjmand, Kokabi Hamidpour, Alavi-Moghadam, Yavari, Shahbazbadr, Rezaei-Tavirani, Gilany and Larjani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.